When the experimental results allow, draft monographs will be published in Pharmeuropa with a peak area repeatability requirement of RSD ≤ 1.0% (n=6) determined on a solution containing the active substance CRS.
A trial period for this policy will run until the end of February 2022; any comments received during the Pharmeuropa public enquiry will be assessed and the policy will be amended or confirmed as appropriate.
See also: